TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3931802
Drug: Yoga exercises
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga exercises including breathing exercises, suryanamaskar, yogasana, pranayama, dhyana, and a devotional session practiced for 65 minutes daily.
Study: 3931802
Drug: Usual drugs
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual drugs (control group).
Study: 29300977
Drug: Salk polio
Normalized name: poliovirus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salk polio vaccine
Study: 27609809
Drug: AS03-adjuvanted vaccines
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03-adjuvanted vaccines (low or medium dose of hemagglutinin with AS03A or AS03B)
Study: 27609809
Drug: Adjuvanted vaccines
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted vaccines
Study: 21291034
Drug: 6 mg/day
Normalized name: EMSAM 6 MG/Day 24HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/day 17beta‐estradiol (E2) orally with progesterone vaginal gel
Study: 21291034
Drug: Progesterone vaginal
Normalized name: progesterone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone vaginal gel without 6 mg/day 17beta‐estradiol (E2)
Study: 18344178
Drug: Antioxidant tablets
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant tablets
Study: 12053635
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 to 100 mg/d)
Study: 12053635
Drug: St John's
Normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St John's wort (900 to 1800 mg/d)
Study: 6354607
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg proglumetacin twice daily
Study: 25416642
Drug: 24 IU
Normalized name: Nasopro 24
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 24 IU intranasal oxytocin (OT)
Study: 25416642
Drug: 20 IU
Normalized name: Calcium/Phosphorus/Vitamin D 105 MG-81 MG-120 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 IU intranasal vasopressin (AVP)
Study: 8656259
Drug: Etoposide 2
Normalized name: etoposide 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide 2 micrograms/mL
Study: 8656259
Drug: Etoposide 3
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide 3 micrograms/mL
Study: 30620868
Drug: 0.96% zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.96% zinc (zinc oxide, zinc citrate), 1.5% L‐arginine and 1450 ppm fluoride as sodium fluoride in a silica base, Test 1
Study: 30620868
Drug: 0.96% zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.96% zinc (zinc oxide, zinc citrate), 1.5% L‐arginine and 1000 ppm fluoride as sodium fluoride in a silica base, Test 2
Study: 27264058
Drug: 800 IU
Normalized name: Vitamin E 800 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 IU cholecalciferol daily
Study: 29423540
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (ACEI)
Study: 1725911
Drug: High-dose verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose verapamil treatment (Isoptin RR 240 mg twice daily)
Study: 1725911
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of nifedipine four times daily
Study: 1725911
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg of diltiazem three times daily
Study: 20693587
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg per kg of body weight)
Study: 14556918
Drug: Various chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various chemotherapy regimens for advanced NSCLC
Study: 14556918
Drug: Platinum and/or
Normalized name: Platinum and/or platinum compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum and/or taxane and combination regimens
Study: 1726209
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil suspension (3 and 6 mg/kg)
Study: 7036336
Drug: Pirenzepine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (75 mg daily)
Study: 31876200
Drug: MTX +
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX + CsA (7.5 mg MTX and 2.5 mg/kg CsA)
Study: 31876200
Drug: MTX +
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX + Placebo (7.5 mg MTX and placebo)
Study: 25782170
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ambroxol (AXS)
Study: 25782170
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg ambroxol (AXS)
Study: 25782170
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg ambroxol (AXS)
Study: 21324570
Drug: Quercetin 4x500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin 4x500 mg orally within 24 hours
Study: 26687616
Drug: 5-aminolevulinic acid
Normalized name: 5-aminolevulinic acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminolevulinic acid photodynamic therapy (ALA-PDT)
Study: 19470041
Drug: 5% imiquimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% imiquimod cream (IMIQ)
Study: 17481859
Drug: Rapid intravenous
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid intravenous administration of meta-chlorophenylpiperazine (m-CPP) at a dosage of 0.1 mg/kg
Study: 15047131
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg rhIGF‐I/IGFBP‐3 for one‐week intervals
Study: 9551246
Drug: Ceftriaxone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (100 mg/kg on the first day followed by 75 mg/kg/day)
Study: 9551246
Drug: Cefotaxime (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (200 mg/kg/day in four divided doses)
Study: 233545
Drug: Oral metaproterenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metaproterenol administered daily for 3 months
Study: 31636172
Drug: Metformin or
Normalized name: metformin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin or placebo
Study: 21991942
Drug: Pre-bronchodilator lung
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-bronchodilator lung function
Study: 21991942
Drug: Post-bronchodilator lung
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-bronchodilator lung function
Study: 21991942
Drug: Pre-bronchodilator lung
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-bronchodilator lung function (Stage 3 or 4 disease)
Study: 21991942
Drug: Post-bronchodilator lung
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-bronchodilator lung function (Stage 3 or 4 disease)
Study: 21991942
Drug: Pre-bronchodilator lung
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-bronchodilator lung function (Year 5 sample)
Study: 21991942
Drug: Post-bronchodilator lung
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-bronchodilator lung function (Year 5 sample)
Study: 16867142
Drug: Treatment effects
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment effects analysis using fecal terminal restriction fragment length polymorphism data sets
Study: 6468034
Drug: 3 X
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 X 1500 mg Cefuroxim (Zinazef) for three days, starting 1 h prior to the operation
Study: 24003241
Drug: Guaifenesin (GGE)
Normalized name: Guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guaifenesin (GGE) 600 mg extended-release tablets, taken twice daily for 8 days
Study: 19930235
Drug: Oral Naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Naltrexone + Brief Behavioral Compliance Enhancement Therapy (BBCET) + treatment as usual (TAU)
Study: 10839588
Drug: Protease Inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease Inhibitor (PI)
Study: 12390317
Drug: Non-Nucleoside Reverse
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
Study: 8749873
Drug: Diltiazem (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (10 mg) intravenous administration
Study: 28973363
Drug: Lung recruitment
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung recruitment maneuver and PEEP titration according to best respiratory-system compliance (n=501)
Study: 28973363
Drug: Lung recruitment
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung recruitment maneuver and PEEP titration (n=501)
Study: 14978636
Drug: Dietary changes,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary changes, use of laxatives, cognitive and behavioral interventions (toilet training)
Study: 14978636
Drug: Antidiarrheal agents
Normalized name: ANTIDIARRHEAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidiarrheal agents
Study: 9387948
Drug: Nasal eupnoeic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal eupnoeic inhalation of cold dry air (‐5 degrees C)
Study: 30559807
Drug: Diet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet therapy for three months
Study: 30559807
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no diet therapy)
Study: 23592701
Drug: Early thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early thoracic radiotherapy (TRT) administered concurrently with the first cycle of chemotherapy
Study: 23592701
Drug: Late thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late thoracic radiotherapy (TRT) administered concurrently with the third cycle of chemotherapy
Study: 12559643
Drug: Five courses
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five courses of therapy
Study: 12559643
Drug: Four courses
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four courses of therapy
Study: 12559643
Drug: Five courses
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five courses of therapy (early results)
Study: 12559643
Drug: Four courses
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four courses of therapy (early results)
Study: 7847530
Drug: Norplant contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norplant contraceptive implants (immediate insertion within 48 hours of delivery)
Study: 1942508
Drug: Midazolam 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.05 mg.kg‐1 + 10 ml saline
Study: 1942508
Drug: Midazolam 0.1
Normalized name: midazolam 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.1 mg.kg‐1 + 10 ml saline
Study: 1942508
Drug: Saline only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline only (10 ml)
Study: 31157368
Drug: National priority
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: National priority for HIV testing and treatment
Study: 15015438
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Bushen Jianpi Recipe (BJR) and low dosage erythropoietin (EPO) - 50 IU/kg subcutaneous injection twice a week and oral intake of BJR, one dose per day for 3 months.
Study: 15015438
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) alone - 50 IU/kg subcutaneous injection three times a week for 3 months.
Study: 9395702
Drug: Acupuncturists/Traditional Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncturists/Traditional Chinese Medicine
Study: 7933527
Drug: Biapenem (L-627)
Normalized name: L
DrugBank: Biapenem (DB13028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biapenem (L-627) 6 mg/kg
Study: 7933527
Drug: Biapenem (L-627)
Normalized name: L
DrugBank: Biapenem (DB13028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biapenem (L-627) 12 mg/kg
Study: 7933527
Drug: Biapenem (L-627)
Normalized name: L
DrugBank: Biapenem (DB13028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biapenem (L-627)
Study: 3125800
Drug: Intravenous feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous feeding (IVF) alone
Study: 3125800
Drug: 1 hour
Normalized name: Product containing precisely estradiol 312.5 nanogram/1 hour prolonged-release vaginal ring (clinical drug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 hour of submaximal (51% of VO2max) stationary bicycle exercise daily during IVF
Study: 31823130
Drug: Dotinurad (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dotinurad (1 mg) administered orally
Study: 28930490
Drug: Tezacaftor (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezacaftor (100 mg every day) and ivacaftor (150 mg every 12 h)
Study: 28625368
Drug: Aspirin 100mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100mg/day
Study: 18214943
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (30 mg elemental Zn daily for 1 year)
Study: 17030773
Drug: Lamotrigine in
Normalized name: Product containing lamotrigine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine in combination with valproate
Study: 17030773
Drug: Users of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Users of oral contraceptives comedicated with valproate
Study: 14646388
Drug: ebastine 20
Normalized name: ebastine
DrugBank: Ebastine (DB11742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ebastine 20 mg
Study: 17345837
Drug: fexofenadine 120
Normalized name: fexofenadine hydrochloride 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: fexofenadine 120 mg
Study: 10966901
Drug: Standard TPN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard TPN solution (glutamine-free)
Study: 9007124
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m2 as a 3-hour infusion followed by carboplatin at a dose based on a target area under the concentration-time curve of 6 mg x min/mL.
Study: 9007124
Drug: Immediate surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate surgery after two courses of neoadjuvant chemotherapy for responding patients.
Study: 9007124
Drug: Two courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two courses of neoadjuvant chemotherapy for nonresponders before surgery.
Study: 29061183
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) group (FG) supplemented with 2 g/day of FO concentrate containing 1.8 g of n-3 fatty acids for 30 days
Study: 29061183
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (PG) received 2 g/day of mineral oil
Study: 21263414
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of proton pump inhibitors (PPIs)
Study: 21263414
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen (40 mg bolus twice a day for 3 days) of proton pump inhibitors (PPIs)
Study: 21263414
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of PPIs
Study: 17366253
Drug: Prize-based incentives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prize-based incentives plus treatment as usual (TAU)
Study: 15545559
Drug: Standard topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard topical hemostatic agents
Study: 11273851
Drug: Low-dose vitamin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vitamin B-6 (1.6 mg/d) for 12 weeks
Study: 9500719
Drug: IFN-alpha2a 3
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha2a 3 million units three times per week + Tenoxicam (20 mg/day) during 6 months
Study: 7850042
Drug: Home program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home program (n = 12) - Cooksey-Cawthorne eye-head exercises performed at home daily for 12 weeks
Study: 3416548
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A cream (1,000 IU/g)
Study: 3416548
Drug: Control cream
Normalized name: BENZOYL PEROXIDE 3 mg in 60 mL TOPICAL LIQUID [Acnecare Dermacontrol Cream]
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control cream (without vitamin A)
Study: 31369180
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of normal saline dressing and 2% mupirocin ointment
Study: 22082702
Drug: Knowledge and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge and Behavior (K&B) therapy
Study: 8377718
Drug: Diuretic (hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic (hydrochlorothiazide and triamterene)
Study: 2854738
Drug: ACTH or
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH or Prednisone therapy
Study: 24328847
Drug: A compound
Normalized name: Soma Compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: A compound gel containing four amino acids and sodium hyaluronate (Aminogam(®), Errekappa, Italy)
Study: 24328847
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment involving a drug or gel (Control Group)
Study: 19661804
Drug: Eritoran tetrasodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eritoran tetrasodium 105 mg
Study: 19661804
Drug: Eritoran tetrasodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eritoran tetrasodium 45 mg
Study: 19661804
Drug: Eritoran tetrasodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eritoran tetrasodium 105 mg (high risk subgroup)
Study: 19661804
Drug: Eritoran tetrasodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eritoran tetrasodium 105 mg (low risk subgroup)
Study: 18382689
Drug: Mild anemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild anemia (hemoglobin concentration between 10.0 and 11.9 g/dL in women and 10.0 and 12.9 g/dL in men)
Study: 12771858
Drug: Short-term therapy
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term therapy with alprostadil (PGE(1))
Study: 6663640
Drug: Long-term therapy
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term therapy
Study: 10608215
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg cisapride p.o.
Study: 1962892
Drug: Penbutolol 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol 40 mg/day orally
Study: 7439241
Drug: Metoprolol 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 300 mg
Study: 7439241
Drug: Metoprolol 200
Normalized name: metoprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 200 mg slow-release
Study: 31185312
Drug: Paravertebral block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paravertebral block (PVB) with 10 ml ropivacaine 0.5% at each level from T12 to L1
Study: 31185312
Drug: Subarachnoid block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subarachnoid block (SAB) with 15 mg ropivacaine 0.5% at L3–L4 level
Study: 28220309
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis (applied to Groups M and S)
Study: 12118903
Drug: Darusentan 100
Normalized name: Darusentan
DrugBank: Darusentan (DB04883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darusentan 100 mg
Study: 19748665
Drug: Darusentan 300
Normalized name: Darusentan
DrugBank: Darusentan (DB04883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darusentan 300 mg
Study: 20509875
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acids (1 g daily)
Study: 15302013
Drug: Low-dose rosuvastatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rosuvastatin (10 mg daily)
Study: 31513165
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment (oral intake of Jermuk mineral water, acupuncture, iodine‐bromine baths, massage, exercise therapy, therapeutic enemas)
Study: 19463204
Drug: Combination inhaled
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination inhaled corticosteroid and long‐acting beta(2)‐agonist (ICS/LABA) maintenance medication
Study: 17245343
Drug: TEGAFIRI (UFT
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEGAFIRI (UFT 250 mg m(‐2) day days 1‐14, LV 90 mg day days 1‐14, irinotecan 240 mg m(‐2) day 1; q21)
Study: 17245343
Drug: TEGAFOX (UFT
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEGAFOX (UFT 250 mg m(‐2) day days 1‐14, LV 90 mg day days 1‐14, oxaliplatin 120 mg m(‐2) day 1; q21)
Study: 15738536
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg via 15-minute infusions every 4 weeks for 1 year)
Study: 12118902
Drug: Limited anti-IL-2R
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Limited anti-IL-2R monoclonal antibody (daclizumab) 2 mg/kg intraoperatively
Study: 27296660
Drug: Evaluation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluation of Treatment (EOT) measure
Study: 27296660
Drug: Treatment satisfaction
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment satisfaction factor